<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02973386</url>
  </required_header>
  <id_info>
    <org_study_id>CCRT-AC-HRDM-NPC</org_study_id>
    <nct_id>NCT02973386</nct_id>
  </id_info>
  <brief_title>Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients</brief_title>
  <official_title>Randomized Trial of Concurrent Cisplatin Chemoradiotherapy Plus Capecitabine Adjuvant Chemotherapy vs Concurrent Cisplatin Chemoradiotherapy Alone for Patients With Local Advanced Nasopharyngeal Carcinoma at High Risk of Distant Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized,controlled,prospective phase III clinical trial. The purpose of this
      study is to evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with
      or without capecitabine as adjuvant chemotherapy in Local Advanced Nasopharyngeal Carcinoma
      at High Risk of Distant Metastasis.Exploring an Individualized comprehensive treatment plan
      which is reasonable,effective,low toxicity and fitting with Modern radiotherapy techniques
      for Local Advanced Nasopharyngeal Carcinoma at High Risk of Distant Metastasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Five-year Distance Metastasis Free Survival</measure>
    <time_frame>Five years</time_frame>
    <description>Defined as the time in months from first dose of cisplatin until distant metastasis is observed or death occurs due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Five-year Local- Regional failure free survial</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Five-year overall survival rate</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the acute toxicity with CTCAEv4.03 when concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the late toxicity with the RTOG/EORTC criterion when concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy is used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">278</enrollment>
  <condition>Local Advanced High Risk Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Concurrent chemoradiation + adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent chemoradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMRT combine with cisplatin concurrent chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMRT combine with cisplatin concurrent chemotherapy</intervention_name>
    <description>Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.</description>
    <arm_group_label>Concurrent chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy</intervention_name>
    <description>Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.</description>
    <arm_group_label>Concurrent chemoradiation + adjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III)

          -  Clinical stage III~IVb(UICC/AJCC 7th)

          -  Meet at least one factor below :1 primary tumor SUVmax&gt;10 in 18F-FDG PET/CT;2
             T3-4N2M0; 5 T1-4N3M0;6 EBV-DNA PCR quantitative＞2×10E4 copy/l(pre-treatment).

          -  No distant metastasis

          -  Karnofsky Performance Status Scale≥70

          -  WBC count ≥ 4×109/L，neutrophil differential count≥ 1.5×109/L,Hemoglobin ≥ 90g/L，
             platelet count ≥ 100×109/L

          -  ALT or AST ≤2.5×ULN,bilirubin ≤2.5×ULN,Serum creatinine ≤1.5×ULN or Serum creatinine
             clearance≥60ml/min

          -  Sign the informed consent.

        Exclusion Criteria:

          -  Angle of sexual squamous cell carcinomas and basal cell layout, squamous cell
             carcinomas

          -  Younger than 18 years old or older than 70 years old

          -  Are receiving other drugs treanment

          -  kidney disease

          -  Have suffered from other tumor or now suffering from other tumor

          -  Have recieved chemotherapy or radiotherapy

          -  Pregnancy or lactation

          -  unstable heart disease need timely treatment

          -  Severe cerebrovascular disease/canker/psychosis/uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhao chong, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>miao jingjing</last_name>
    <phone>+86-13631355201</phone>
    <email>miaojj@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>wu haijun</last_name>
    <phone>+86-18819200847</phone>
    <email>wuhj@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao chong, M.D</last_name>
      <phone>+86-13902206160</phone>
      <email>zhaochong@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.org.cn</url>
    <description>Home Page of Cancer Center, Sun Yat-sen University</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2016</study_first_posted>
  <last_update_submitted>February 3, 2018</last_update_submitted>
  <last_update_submitted_qc>February 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhao Chong</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Local advanced</keyword>
  <keyword>High Risk</keyword>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

